Posted innews Oncology Otorhinolaryngology
Neoadjuvant Nivolumab plus Chemotherapy Redefines Pathologic Response in Locally Advanced Resectable Head and Neck Cancer
This Phase II trial demonstrates that combining nivolumab with carboplatin and paclitaxel as neoadjuvant therapy for SCCHN achieves a 45% pathologic complete response rate and high 3-year survival, offering a promising strategy for locally advanced, resectable disease.
